FY2025 · ended Dec 31, 2025 · Revenue $3.71B, +65.2% YoY · Filed Feb 12, 2026
Alnylam Pharmaceuticals, Inc. (ALNY) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $3.7 billion and net income of $313.7 million. Free cash flow was $465.4 million. As of Sep 30, 2026 it held $3.6 billion in cash and investments and $249.4 million in total debt.
Revenue (TTM)
$5.01B
+56.2% vs year-ago TTM
Net income (TTM)
$2.65B
+2136.9% vs year-ago TTM
Operating cash flow (TTM)
$955.94M
+351.6% vs year-ago TTM
Free cash flow (TTM)
$806.31M
+382.3% vs year-ago TTM
EPS (TTM)
$19.24
+2058.4% vs year-ago TTM
Dividend per share
None
Shares outstanding
132.62M
+2.4% vs prior year
Net cash
$3.34B
as of Sep 30, 2026
Operating margin
19.5%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ALNY (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Cambridge, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1178670
- Former names
- ALNYLAM PHARMACEUTICALS INC (until Jul 2, 2004)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $3.7B | $2.2B | $1.8B | $1.0B | $844.3M |
| Operating income | $501.6M | -$176.9M | -$282.2M | -$785.1M | -$708.7M |
| Net income | $313.7M | -$278.2M | -$440.2M | -$1.1B | -$852.8M |
| Diluted EPS | $2.33 | -$2.18 | -$3.52 | -$9.30 | -$7.20 |
| Operating cash flow | $524.1M | -$8.3M | $104.2M | -$541.3M | -$641.7M |
| Free cash flow | $465.4M | -$42.6M | $41.9M | -$613.3M | -$718.1M |
| Total assets | $5.0B | $4.2B | $3.8B | $3.5B | $3.6B |
| Total liabilities | $4.2B | $4.2B | $4.1B | $3.7B | $3.1B |
| Stockholders' equity | $789.2M | $67.1M | -$220.6M | -$158.2M | $588.2M |
| Cash and investments | $2.9B | $2.7B | $2.4B | $2.2B | $2.4B |
| Total debt | $270.6M | $271.4M | $284.6M | $303.3M | $321.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Other events
|
Nov 5, 2026 | Nov 2, 2026 |
| 10-Q | Quarterly report | Oct 29, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 29, 2026 | Oct 29, 2026 |
| 10-Q | Quarterly report | Jul 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 30, 2026 | Jul 30, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 27, 2026 | May 20, 2026 |
All 1002 Alnylam Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.